Biorchestra

Executive Summary

Biorchestra is a private biotechnology company developing RNA-based therapeutics for neurological and inflammatory diseases, with a core focus on overcoming delivery challenges including the blood-brain barrier. Its proprietary platform targets central nervous system disorders such as Alzheimer's disease, ALS, and neuroinflammation. Founded in 2013 and based in Daejeon, South Korea (though listed as US), the company has remained in early-stage development with no disclosed funding or pipeline details. The platform's potential to enable CNS delivery of RNA therapeutics represents a significant opportunity, but the lack of public milestones and limited transparency contribute to substantial execution risk. Biorchestra's success hinges on advancing its lead programs into clinical trials and establishing strategic partnerships to validate its delivery technology.

Upcoming Catalysts (preview)

• Q4 2026Initiation of first-in-human trial for Alzheimer's candidate20% success
• Q2 2026Publication of preclinical data for ALS program60% success
• Q3 2026Announcement of partnership or licensing deal for delivery platform30% success